Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): Development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo

Current Pharmaceutical Design

Volumn 9, Issue 19, 2003, Pages 1529-1543

  Reuning, Ute ^a   Sperl, Stefan ^b   Kopitz, Charlotte ^c   Kessler, Horst ^c   Krüger, Achim ^c   Schmitt, Manfred ^a   Magdolen, Viktor ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Wilex Biotechnology GmbH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antagonists; Cancer therapy; D amino acid; Tumor invasion; Urokinase; Urokinase receptor

Indexed keywords

A6 PEPTIDE; AMILORIDE DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTIESTROGEN; ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; APROTININ; CISPLATIN; COUMARIN DERIVATIVE; CYCLOPEPTIDE; GLYCINE DERIVATIVE; HYBRID PROTEIN; IMMUNOGLOBULIN G; MATRIX METALLOPROTEINASE; MESOPORPHYRIN; MONOCLONAL ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCLONAL ANTIBODY; PORPHYRIN DERIVATIVE; RECOMBINANT PROTEIN; SERINE PROTEINASE; SYNTHETIC PEPTIDE; TAMOXIFEN; THIOPHENE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ULINASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; DRUG DESIGN; DRUG EFFECT; DRUG SYNTHESIS; DRUG TARGETING; EVIDENCE BASED MEDICINE; EXTRACELLULAR MATRIX; EXTRAVASATION; GENE TRANSFER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; METASTASIS INHIBITION; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BINDING SITES; HUMANS; RECEPTORS, CELL SURFACE; TECHNOLOGY, PHARMACEUTICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0037967309     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454612     Document Type: Review

References (107)

1. Andreasen, P. A.; Egelund, R., Petersen, H. H. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol. Life Sci. 2000, 57, 25-40.
2. Reuning, U.; Magdolen, V.; Wilhelm, O.; Fischer, K.; Lutz, V.; Graeff, H.; Schmitt, M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 1998, 13, 893-906.
3. Rabbani, S. A.; Mazar, A. P. The role of the plasminogen activation system in angiogenesis and metastasis. Surg. Oncol. Clin. N. Am. 2001, 10, 393-415.
4. del Rosso, M.; Fibbi, G.; Pucci, M.; D'Alessio, S.; del Rosso, A.; Magnelli, L.; Chiarugi, V. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin. Exp. Metast. 2002, 19, 193-207.
5. Schmitt M.; Harbeck N.; Thomssen C.; Wilhelm O.; Magdolen V.; Reuning U.; Ulm K.; Höfler H.; Jánicke F.; Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 1997, 78, 285-296.
6. Look, M. P.; van Putten, W. L.; Duffy, M. J.; Harbeck, N.; Christensen, I. J.; Thomssen, C.; Kates, R.; Spyratos, F.; Ferno, M.; Eppenberger-Castori, S.; Sweep, C. G.; Ulm, K.; Peyrat, J. P.; Martin, P. M.; Magdelenat, H.; Brünner N.; Duggan, C.; Lisboa, B. W.; Bendahl, P. O.; Quillien, V.; Daver, A., Ricolleau, G.; Meijer-van Gelder, M. E.; Manders, P.; Fiets, W. E.; Blankenstein, M. A.; Broet, P.; Romain, S.; Daxenbichler, G.; Windbichler, G.; Cufer, T.; Borstnar, S.; Kueng, W.; Beex, L. V.; Klijn, J. G.; O'Higgins, N.; Eppenberger, U.; Jänicke, F.; Schmitt, M.; Foekens, J. A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 2002, 94, 116-128.
7. Jänicke, F.; Prechtl, A.; Thomssen, C.; Harbeck, N.; Meisner, C.; Untch, M.; Sweep, C. G.; Selbmann, H. K.; Graeff, H.; Schmitt, M. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 2001, 93, 913-920.
8. Harbeck, N.; Kates, R. E.; Schmitt, M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol. 2002, 20, 1000-1007.
9. Duffy, M. J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin. Chem. 2002, 48, 1194-1197.
10. Schmitt, M.; Wilhelm, O. G.; Reuning, U.; Krüger, A.; Harbeck, N.; Lengyel, E.; Graeff, H.; Gänsbacher, B.; Kessler, H.; Bürgle, M.; Stürzebecher, J.; Magdolen, V. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinol. Proteol. 2000, 14, 114-132.
11. Muehlenweg, B.; Sperl, S.; Magdolen, V.; Schmitt, M.; Harbeck, N. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Fxpert. Opin. Biol. Ther. 2001, 1, 683-691.
12. Deng, G.; Curriden, S. A.; Wang. S.; Rosenberg, S.; Loskutoff, D. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J. Cell Biol. 1996, 134, 1563-1571.
13. Wind, T.; Hansen, M.; Jensen, J. K.; Andreasen, P. A. The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol. Chem. 2002, 383, 21-36.
14. Ploug, M.; Gårdsvoll, H.; Jorgensen, T. J.; Lonborg Hansen, L.; Danø, K. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy. Biochem. Soc. Trans. 2002, 30, 177-183.
15. Behrendt, N.; Rønne, E.; Danø, K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol. Chem. 1995, 376, 269-279.
16. Mondino, A.; Resnati, M.; Blasi, F. Structure and function of the urokinase receptor. Thromb. Haemost. 1999, 82, 19-22.
17. Preissner, K. T.; Kanse, S. M.; May, A. E. Urokinase receptor: a molecular organizer in cellular communication. Curr. Opin. Cell. Biol. 2000, 12, 621-628.
18. Conese, M.; Blasi, F. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol. Chem. Hoppe Seyler 1995, 376, 143-155.
19. Andersen, O. M.; Petersen, H. H.; Jacobsen, C.; Moestrup, S. K.; Etzerodt, M.; Andreasen, P. A.; Thogersen, H. C. Analysis of a two-domain binding site for the urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex in low-density-lipoprotein-receptor-related protein. Biochem. J. 2001, 357, 289-296.
20. Czekay, R. P.; Kuemmel, T. A.; Orlando, R. A.; Farquhar, M. G. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 2001, 12, 1467-1479.
21. Nykjaer, A.; Conese, M.; Christensen, E. I., Olson, D., Cremona, O., Gliemann, J., Blasi, F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 1997, 16, 2610-2620.
22. Stepanova, V. V.; Tkachuk, V. A. Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Mosc) 2002, 67, 109-118.
23. Ma, Z.; Webb, D. J.; Jo, M.; Gonias, S. L. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J. Cell Sci. 2001, 114, 3387-3396.
24. Liu, D.; Aguirre Ghiso, J.; Estrada, Y.; Ossowski, L. EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002, 1, 445-457.
25. Ossowski, L.; Aguirre-Ghiso, J. A. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 2000, 12, 613-620.
26. Blasi, F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol. Today 1997, 18, 415-417.
27. Fazioli, F.; Resnati, M.; Sidenius, N.; Higashimoto, Y.; Appella, E.; Blasi, F. A Urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997, 16, 7279-7286.
28. Resnati, M.; Pallavicini, I.; Wang, J.M.; Oppenheim, J.; Serhan, C. N.; Romano, M.; Blasi, F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 1359-1364.
29. Chapman, H. A.; Wei, Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb. Haemost. 2001, 86, 124-129.
30. Schwartz, M. A. Integrin signaling revisited. Trends Cell. Biol. 2001, 12, 466-470.
31. Giancotti, F. G.; Rouslahti, E. Integrin signaling. Science 1999, 285, 1028-1032.
32. Loskutoff, D. J.; Curriden, S. A.; Hu, G.; Deng, G. Regulation of cell adhesion by PAI-1. APMIS 1999, 107, 54-61.
33. Kusch, A.; Tkachuk, S.; Haller, H.; Dietz, R.; Gulba, D. C.; Lipp, M.; Dumler, I. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. J. Biol. Chem. 2000, 275, 39466-39473.
34. Degryse, B.; Orlando, S.; Resnati, M.; Rabbani, S. A.; Blasi, F. Urokinase/urokinase receptor and VN/alpha(v)β(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways. Oncogene 2001, 20, 2032-2043.
35. Bajou, K.; Lewalle, J. M.; Martinez, C. R.; Soria, C.; Lu, H.; Noel, A.; Foidart, J. M. Human breast adenocarcinoma cell lines promote angiogenesis by providing cells with uPA-PAI-1 and by enhancing their expression. Int. J. Cancer 2002, 100, 501-506.
36. Guo, Y. J.; Mazar, A. P.; Lebrun, J. J.; Rabbani, S. A. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res. 2002, 62, 4678-4684.
37. Apparailly, F.; Bouquet, C.; Millet, V.; Noel, D.; Jacquet, C.; Opolon, P.; Perricaudet, M.; Sany, J.; Yeh, P.; Jorgensen, C. Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis. Gene Ther. 2002, 99, 192-200.
38. Pepper, M. S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1104-1117.
39. Sperl, S.; Mueller, M. M.; Wilhelm, O. G.; Schmitt, M.; Magdolen, V.; Moroder, L. The uPA/uPA-receptor system as a target for tumor therapy. Drug News Perspect. 2001, 14, 401-411.
40. Appella, E.; Robinson, E. A.; Ullrich. S. J.; Stoppelli, M. P.; Corti, A.; Cassani, G.; Blasi, F. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J. Biol. Chem. 1987, 262, 4437-4440.
41. Mukhina, S.; Stepanova, V.; Traktouev, D.; Poliakov, A.; Beabealashvilly, R.; Gursky, Y.; Minashkin, M.; Shevelev, A.; Tkachuk, V. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J. Biol. Chem. 2000, 275, 16450-16458.
42. Gårdsvoll, H.; Danø, K.; Ploug, M. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis. J. Biol. Chem. 1999, 274, 37995-38003.
43. Luther, T.; Magdolen, V.; Albrecht, S.: Kasper, M.; Riemer, C.; Kessler, H.; Graeff, H.; Müller, M.; Schmitt, M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. Pathol. 1997, 150, 1231-1244.
44. Ploug, M. Identification of specific sites involved in ligand binding by photoaffinity labeling or the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand- binding site. Biochemistry 1998, 37, 16494-16505.
45. Hansen, A. P.; Petros, A. M.; Meadows, R. P.; Fesik, S. W. Backbone dynamics of a two-domain protein: 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994, 33, 15418-15424.
46. Hansen, A. P.; Petros, A. M.; Meadows, R. P.; Nettesheim, D. G.; Mazar, A. P.; Olejniczak, E. T.; Xu, R. X.; Pederson, T. M.; Henkin, J.; Fesik, S. W. Solution structure of the amino-terminal fragment of urokinase-type plasminogen activator. Biochemistry 1994, 33, 4847-4864.
47. Magdolen, V.; Rettenberger, P.; Koppitz, M.; Goretzki, L.; Kessler, H.; Weidle, U. H.; König, B.; Graeff, H.; Schmitt, M.; Wilhelm O. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur. J. Biochem. 1996, 237, 743-751.
48. Bürgle, M.; Koppitz, M.; Riemer, C.; Kessler, H.; König, B.; Weidle, U. H.; Kellermann, J.; Lottspeich, F.; Graeff, H.; Schmitt, M.; Goretzki, L.; Reuning, U.; Wilhelm, O.; Magdolen, V. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol. Chem. 1997, 378, 231-237.
49. Muehlenweg, B.; Assfalg-Machleidt, I.; Gil-Parrado, S.; Bürgle, M.; Creutzburg, S.; Schmitt, M.; Auerswald, E. A.; Machleidt, W.; Magdolen, V. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand interaction. Cystatin with a urokinase receptor binding site. J. Biol. Chem. 2000, 275, 33562-33566.
50. 19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol. Chem. 2001, 382, 1197-1205.
51. Kessler, H.; Bürgle, M.; Graeff, H.; Magdolen, V.; Schmitt, M.; Wilhelm, O.; Riemer, C. (Wilex AG). Inhibitors for urokinase receptor. Pat. Apl. WO 9846632, 1998.
52. Wermuth, J.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Stereoisomerism and biological activity of the selective and superactive αvβ3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide. J. Am. Chem. Soc. 1997, 119, 1329-1335.
53. Guthaus, E.; Bürgle, M.; Schmiedeberg, N.; Hocke, S.; Eickler, A.; Kramer, M. D.; Sweeep, C. G.; Magdolen, V.; Kessler, H.; Schmitt, M. uPA-silica-Particles (SP-uPA): a novel analytical system to investigate uPA-UPAR interaction and to test synthetic uPAR antagonists as potential cancer therapeutics. Biol. Chem. 2002, 383, 207-216.
54. Schmiedeberg, N.; Schmitt, M.; Rölz, C.; Truffault, V.; Sukopp, M.; Bürgle, M.; Wilhelm, O. G.; Schmalix, W.; Magdolen, V.; Kessler, H. Synthesis, solution structure, and biological evaluation of urokinase-type plasminogen activator (uPA)-derived receptor binding domain mimetics. J. Med. Chem. 2002, 45, 4984-4994.
55. Schmiedeberg, N.; Kessler, H.; Potthoff, N.; Bürgle, M.; Wilhelm, O. G. (Wilex AG). Cyclic peptidomimetic urokinase receptor antagonists. Pat. Apl. WO 0105911, 2001.
56. Schmiedeberg, N.; Kessler, H.; Bürgle, M.; Wilhelm, O. G. (Wilex AG). Urokinase peptide structure mimetics. Pat. Apl. WO 0216929, 2002.
57. Goodson, R. J.; Doyle, M. V.; Kaufman, S. E.; Rosenberg, S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA 1994, 91, 7129-7133.
58. Wei, Y.; Lukashev, M.; Simon, D. I.; Bodary, S. C.; Rosenberg, S.; Doyle, M. V.; Chapman, H. A. Regulation of integrin function by the urokinase receptor. Science 1996, 273, 1551-1555.
59. Simon, D. I.; Wei, Y.; Zhang, L.; Rao, N. K.; Xu, H.; Chen, Z.; Liu, Q.; Rosenberg, S.; Chapman, H. A. Identification of a urokinase receptor-integrin interaction site: promiscuous regulator of integrin function. J. Biol. Chem. 2000, 275, 10228-10234.
60. Fong, S.; Doyle, M. V.; Goodson, R. J.; Drummond, R. J.; Stratton, J. R.; McGuire, L.; Doyle, L. V.; Chapman, H. A.; Rosenberg, S. Random peptide bacteriophage display as a probe for urokinase receptor ligands. Biol. Chem. 2002, 383, 149-158.
61. Tressler, R. J.; Pitot, P. A.; Stratton, J. R.; Forrest, L. D.; Zhuo, S. Q.; Drummond, R. J.; Fong, S.; Doyle, M. V.; Doyle, L. V.; Min, H. Y.; Rosenberg, S. Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS 1999, 107, 168-173.
62. Ploug, M.; Østergaard, S.; Holm, A.; Holst-Hansen, C.; Stephens, R. W.; Danø, K. Peptide antagonists of the human urokinase receptor and method for selecting them. Pat. Apl. WO 0001802, 2000.
63. Ploug, M.; Østergaard, S.; Gårdvoll, H.; Kovalski, K.; Holst-Hansen, C.; Holm, A.; Ossowski, L.; Danø, K. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001, 40, 12157-12168.
64. Furka, A.; Sebestyen, F.; Asgedom, M.; Dibo, G. General method for rapid synthesis of multicomponent peptide mixtures. Int. J. Pept. Protein Res. 1991, 37, 487-493.
65. Guo, Y.; Higazi, A. A.; Arakelian, A.; Sachais, B. S.; Cines, D.; Goldfarb, R. H.; Jones, T. R.; Kwaan, H.; Mazar, A. P.; Rabbani, S. A. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 2000, 14, 1400-1410.
66. Drapkin, P. T.; O'Riordan, C. R.; Yi, S. M.; Chiorini, J. A.; Cardella, J.; Zabner, J.; Welsh, M. J. Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J. Clin. Invest. 2000, 105, 589-596.
67. Wilhelm, O.; Weidle, U.; Höhl, S.; Rettenberger, P.; Schmitt, M.; Graeff, H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett. 1994, 337, 131-134.
68. Rosenberg, S.; Spear, K. L.; Martin E. J. Urokinase receptor ligands. Pat. Apl. WO 9640747, 1996.
69. Rosenberg, S.; Spear, K. L.; Martin E. J. Urokinase receptor ligands. Pat. Apl. US 5747458, 1998.
70. König, B.; Zimmermann, G.; De Cillis, G.; di Domenico, R. Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them. Pat. Apl. WO 9906393, 1999.
71. De Cillis, G.; di Domenico, R.; König, B.; Oliva, A. O-substituted hydroxycumaranone derivatives as antitumor and antimetastatic agents. Pat. Apl. WO 9906387, 1999.
72. Blood, C. H.; Neustadt, B. R.; Smith, E. M. Derivatives of aminobenzoic and aminobiphenylcarboxylic acids useful as anti-cancer agents. Pat. Apl. US 6228985, 2001.
73. König, B.; Weidle, U.; Krell, H.-W.; Kilpert, C.; Knipp, B. Porphyrins as urokinase-type plasminogen activator receptor antagonists. Pat. Apl. WO 9731645, 1997.
74. Lutz, V.; Reuning, U.; Krüger, A.; Luther, T.; Pildner von Steinburg, S.; Graeff, H.; Schmitt, M.; Wilhelm, O. G.; Magdolen, V. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol. Chem. 2001, 382, 789-798.
75. Kroon, M. E.; Koolwijk, P.; van Goor, H.; Weidle, U. H.; Collen, A.; van der Pluijm, G.; van Hinsbergh, V. W. Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am. J. Pathol. 1999, 154, 1731-1742.
76. Malinda, K. M.; Nomizu, M.; Chung, M.; Delgado, M.; Kuratomi, Y.; Yamada, Y.; Kleinman, H. K.; Ponce, M. L. Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J. 1999, 13, 53-62.
77. Solberg, H.; Løber, D.; Eriksen, J.; Ploug, M.; Rønne, E.; Behrendt, N.; Danø, K.; Høyer-Hansen, G. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur. J. Biochem. 1992, 205, 451-458.
78. Reuning, U.; Bang, N. U. Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens. Arterioscler. Thromb. 1992, 12, 1161-1170.
79. Fowler, B.; Mackman, N.; Parmer, R. J.; Miles, L. A. Binding of human single chain urokinase to Chinese hamster ovary cells and cloning of hamster u-PAR. Thromb. Haemost. 1998, 80, 148-154.
80. Engelholm, L. H.; Behrendt, N. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species. Biol. Chem. 2001, 382, 435-442.
81. Fischer, K.; Lutz, V.; Wilhelm, O.; Schmitt, M.; Graeff H.; Heiss, P.; Nishiguchi, T.; Harbeck, N.; Kessler, H.; Luiher, T.; Magdolen, V.; Reuning, U. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett. 1998, 438, 101-105.
82. Andreasen, P. A.; Kjoller, L.; Christensen, L.; Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 1997, 72, 1-22.
83. Rabbani, S. A.; Gladu, J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. 2002, 62, 2390-2397.
84. Kobayashi, H.; Gotoh, J.; Fujie, M.; Shinohara, H.; Moniwa, N.; Terao, T. Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer 1994, 57, 727-733.
85. Sato, S.; Kopitz, C.; Schmalix, W. A.; Muehlenweg, B.; Kessler, H.; Schmitt, M.; Krüger, A.; Magdolen, V. High-affinity urokinase-derived cyclic peptidcs inhibiting urokinase/urokinase receptor-interaction: effects on tumor growth and spread. FEBS Lett. 2002, 528, 212-216.
86. Mishima, K.; Mazar, A. P.; Gown, A.; Skelly, M.; Ji, X.-D.; Wang, X.-D.; Jones, T. R.; Cavenee, W. K.; Huang, H.-J. S. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl. Acad. Sci. USA 2000, 97, 8484-8489.
87. Kobayashi, H.; Sugino, D.; She, M. Y.; Ohi, H.; Hirashima, Y.; Shinohara, H.; Fujie, M.; Shibata, K.; Terao, T. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin. Eur. J. Biochem. 1998, 253, 817-826.
88. Min, H. Y.; Doyle, L. V.; Vitt, C. R.; Zandonella, C. L.; Stratton-Thomas, J. R.; Shuman, M. A.; Rosenberg, S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 1996, 56, 2428-2433.
89. Crowley, C. W.; Cohen, R. L.; Lucas, B. K.; Liu, G.; Shuman, M. A.; Levinson, A. D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA 1993, 90, 5021-5025.
90. Luparello, C.; del Rosso, M. In vitro anti-proliferative and anti-invasive role of aminoterminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells. Eur. J. Cancer 1996, 32, 702-707.
91. Zhu, F.; Jia, S.; Xing, G.; Gao, L.; Zhang, L.; He, F. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis. DNA Cell Biol. 2001, 20, 297-305.
92. Li, H.; Lu, H.; Griscelli, F.; Opolon, P.; Sun, L. Q.; Ragot, T.; Legrand, Y.; Belin, D.; Soria, J.; Soria, C.; Perricaudet, M.; Yeh, P. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 1998, 5, 1105-1113.
93. Lefesvre, P.; Attema, J.; van Bekkum, D. Adenoviral gene transfer of angiostatic ATF-BPTI inhibits tumour growth. BMC Cancer 2002, 2, 17.
94. Krüger, A.; Soeltl, R.; Lutz, V.; Wilhelm, O. G.; Magdolen, V.; Rojo, E. E.; Hantzopoulos, P. A.; Graeff, H.; Gansbacher, B.; Schmitt, M. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther. 2000, 7, 292-299.
95. Cavallaro, U.; del Vecchio, A.; Lappi, D. A.; Soria, M. R. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J. Biol. Chem. 1993, 268, 23186-23190.
96. Vallera, D. A.; Li, C.; Jin, N.; Panoskaltsis-Mortari, A.; Hall, W. A. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl. Cancer Inst. 2002, 94, 597-606.
97. Quax, P. H.; Lamfers, M. L.; Lardenoye, J. H.; Grimbergen, J. M.; de Vries, M. R.; Slomp, J.; de Ruiter, M. C.; Kockx, M. M.; Verheijen, J. H.; van Hinsbergh, V. W. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation 2001, 103, 562-569.
98. Lamfers, M. L.; Grimbergen, J. M.; Aalders, M. C.; Havenga, M. J.; de Vries, M. R.; Huisman, L. G.; van Hinsbergh, V. W.; Quax, P. H. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1. Circ. Res. 2002, 91, 945-952.
99. Wada, M.; Wada, N. A.; Shirono, H.; Taniguchi, K.; Tsuchie, H.; Koga, J. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem. Biophys. Res. Commun. 2001, 284, 346-351.
100. Alfano, M.; Sidenius, N.; Panzeri, B.; Blasi, F.; Poli, G. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV replication. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 8862-8867.
101. Cook, A. D.; Braine, E. L.; Campbell, I. K.; Hamilton, J. A. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am. J. Pathol. 2002, 160, 917-926.
102. Busso, N.; Peclat, V.; Van Ness, K.; Kolodziesczyk, E.; Degen, J.; Bugge, T.; So, A. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J. Clin. Invest. 1998, 102, 41-50.
103. Yang, Y. H.; Carmeliet, P.; Hamilton, J. A. Tissue-type plasminogen activator deficiency exacerbates arthritis. J. Immunol. 2001, 167, 1047-1052.
104. Bromme, D. and Kaleta, J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Des. 2002, 8(18), 1639-58.
105. Lee, K. H. Development of short antimicrobial peptides derived from host defense peptides or by combinatorial libraries. Curr. Pharm. Des. 2002, 8(9), 795-813.
106. Rockway, T. W.; Nienaber, V. and Giranda, V. L. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr. Pharm. Des. 2002, 8(28), 2541-58.
107. Roy, K. K. and Sausville, E. A. Early development of cyclin dependent kinase modulators. Curr. Pharm. Des. 2001, 7(16), 1669-87.